基于生物标志物的脓毒症死亡风险分层工具在儿童急性呼吸窘迫综合征中的适配
本研究为前瞻性观察性队列研究,在大学附属PICU纳入152例机械通气的儿童ARDS患者,于ARDS起病24小时内采血检测生物标志物。原儿童脓毒症生物标志物风险模型(Pediatric Sepsis Biomarker Risk Model)和修订版(Pediatric Sepsis Biomarker Risk Model-II)的AUC分别为0.61和0.76,前者表现差、后者表现中等。因此随机选取80%队列(n=122)重新衍生模型,最终模型包含3个生物标志物和年龄,AUC为0.85,与Pediatric Sepsis Biomarker Risk Model比较p<0.001,与Pediatric Sepsis Biomarker Risk Model-II比较p=0.053。在剩余20%(n=30)中测试,测试特征相似。作者结论认为新模型内部测试特征良好,需在更大队列中外部验证。
要点
- 在152例机械通气儿童ARDS中,原Pediatric Sepsis Biomarker Risk Model预测28天死亡风险的AUC为0.61,表现差。
- 修订版Pediatric Sepsis Biomarker Risk Model-II在同一队列中AUC为0.76,表现中等。
- 新衍生的儿童ARDS生物标志物风险模型含3个生物标志物和年龄,AUC为0.85,与Pediatric Sepsis Biomarker Risk Model比较p<0.001,与Pediatric Sepsis Biomarker Risk Model-II比较p=0.053。
- 新模型在剩余20%(n=30)测试集中表现出相似的测试特征。
- 作者结论:新模型内部测试特征良好,需在更大队列中外部验证,并可能为未来儿童ARDS试验提供风险分层和预后富集。
适用人群与场景
- 大学附属PICU中机械通气的儿童ARDS患者,于ARDS起病24小时内采血检测生物标志物。
研究设计与关键结果
- 研究类型:前瞻性观察性队列研究;样本量152例机械通气儿童ARDS;单中心大学附属PICU。
- 原Pediatric Sepsis Biomarker Risk Model预测28天死亡风险的AUC为0.61,Pediatric Sepsis Biomarker Risk Model-II的AUC为0.76。
- 随机选取80%队列(n=122)重新衍生模型,最终模型含3个生物标志物和年龄,AUC为0.85,与Pediatric Sepsis Biomarker Risk Model比较p<0.001,与Pediatric Sepsis Biomarker Risk Model-II比较p=0.053。
- 新模型在剩余20%(n=30)测试集中表现出相似的测试特征。
证据类型、等级与局限
- 证据类型:前瞻性观察性队列研究。
- 局限:作者指出新模型需在更大队列中外部验证。
对床旁实践的改变
- 作者认为新衍生的儿童ARDS生物标志物风险模型内部测试特征良好,可能为未来儿童ARDS试验提供改进的风险分层和预后富集,但需外部验证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: The original Pediatric Sepsis Biomarker Risk Model and revised (Pediatric Sepsis Biomarker Risk Model-II) biomarker-based risk prediction models have demonstrated utility for estimating baseline 28-day mortality risk in pediatric sepsis. Given the paucity of prediction tools in pediatric acute respiratory distress syndrome, and given the overlapping pathophysiology between sepsis and acute respiratory distress syndrome, we tested the utility of Pediatric Sepsis Biomarker Risk Model and Pediatric Sepsis Biomarker Risk Model-II for mortality prediction in a cohort of pediatric acute respiratory distress syndrome, with an a priori plan to revise the model if these existing models performed poorly.
DESIGN: Prospective observational cohort study.
SETTING: University affiliated PICU.
PATIENTS: Mechanically ventilated children with acute respiratory distress syndrome.
INTERVENTIONS: Blood collection within 24 hours of acute respiratory distress syndrome onset and biomarker measurements.
MEASUREMENTS AND MAIN RESULTS: In 152 children with acute respiratory distress syndrome, Pediatric Sepsis Biomarker Risk Model performed poorly and Pediatric Sepsis Biomarker Risk Model-II performed modestly (areas under receiver operating characteristic curve of 0.61 and 0.76, respectively). Therefore, we randomly selected 80% of the cohort (n = 122) to rederive a risk prediction model for pediatric acute respiratory distress syndrome. We used classification and regression tree methodology, considering the Pediatric Sepsis Biomarker Risk Model biomarkers in addition to variables relevant to acute respiratory distress syndrome. The final model was comprised of three biomarkers and age, and more accurately estimated baseline mortality risk (area under receiver operating characteristic curve 0.85, p < 0.001 and p = 0.053 compared with Pediatric Sepsis Biomarker Risk Model and Pediatric Sepsis Biomarker Risk Model-II, respectively). The model was tested in the remaining 20% of subjects (n = 30) and demonstrated similar test characteristics.
CONCLUSIONS: A validated, biomarker-based risk stratification tool designed for pediatric sepsis was adapted for use in pediatric acute respiratory distress syndrome. The newly derived Pediatric Acute Respiratory Distress Syndrome Biomarker Risk Model demonstrates good test characteristics internally and requires external validation in a larger cohort. Tools such as Pediatric Acute Respiratory Distress Syndrome Biomarker Risk Model have the potential to provide improved risk stratification and prognostic enrichment for future trials in pediatric acute respiratory distress syndrome.
参考来源
- Yehya N, Wong HR. Adaptation of a Biomarker-Based Sepsis Mortality Risk Stratification Tool for Pediatric Acute Respiratory Distress Syndrome. Crit Care Med. 2018. PMID: 28991832. doi:10.1097/CCM.0000000000002754
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。